We have recently updated our Privacy Policy. You agree to our updated terms by closing this message box or by continuing to use our site. To read the updated policy, click here
Welcome
We're constantly striving to provide a better experience for our users, to help you invest better, and to keep your data safe and secure. We have updated our Privacy Policy as of May 24, 2018, in accordance with the General Data Protection Regulation (GDPR) law, which will come into effect on May 25, 2018. Please provide consent to continue accessing all of the great content that MarketSmith India has provided you in the past.
Dear valued William O'Neil + Co. user or visitor:
Your privacy is very important to us. As you may be aware, the European Union's General Data Protection Regulation ("GDPR") goes into effect on May 25, 2018. The GDPR is a data privacy regulation that imposes certain data protection obligations on "data controllers" (i.e., companies that decide how your information will be used) and makes the protection of "personal data" (e.g., your name and e-mail address) a fundamental right for residents of the European Union ("EU"). As MarketSmith India processes your personal data as a data controller, we feel it is important to explain how your information will be processed, how it will be shared, how it will be protected, and your rights under the GDPR. Such explanations are provided in our updated Privacy Policy. Please review these documents carefully before you start or continue to use our Services.
Please note that by clicking "Accept and Close" below, you are confirming that you have reviewed the Privacy Policy, understand their contents, are expressly consenting to MarketSmith India's processing activities as detailed therein (including the processing of your data in the United States), and agree to be bound by such agreements. Please note that under the GDPR, you are able to withdraw your consent to MarketSmith India's processing activities at any time. However, even if you withdraw your consent, please note that MarketSmith India will still likely have a legal basis for processing your information, including the bases of contractual necessity and/or legitimate interests. Accordingly, if you do not want MarketSmith India to process your information as detailed in the Privacy Policy, you should refrain from using or accessing the Services.
The answer you seek is only a question away.
We are always working to make MarketSmith India exactly what you need for your stock market investment needs. It's your feedback that helps us decide which features to build on and what improvements are needed to be made in our product and services. Do let us know how we can make this application more helpful. Please leave your comments below. Thank you!
This is a process for estimating your financial risk-taking capacity and understanding the (psychological) risk tolerance level. We have compiled the following questions which will help us to evaluate both the parameters. Please answer all the questions by picking the option that best indicates how you feel about each.
The selected Risk Profile is not suitable for Equity investing as it involves risk. Do you still want to continue?
Yes, I understand and want to continue?
Because we value you as our customer, we want to make you aware that our Legal Agreement has been updated.We request you to take review and accept the same.
You continued use of our products is your agreement to updated Legal Agreement. if you have any queries, please write to us at marketsmithindia@williamoneilindia.com
The MarketSmith India Evaluation gives you an unbiased instant assessment of over 3,900 stocks. Quickly evaluate a stock's rank with our Master Score, a summary proprietary rating, which is based on the EPS, Price Strength, Buyer Demand, Group Rank ratings.
The Evaluation view is composed of a stock chart and the stock-specific data in the Details Tab. This view efficiently combines the key stock information you need to validate your decision to buy or sell or to commit to further research.
The Chart Overview support content will provide you with an orientation of the data items available on the chart and how they may be used to quickly evaluate a stock.
The Details Tab breaks down the data grid so you can better understand the comprehensive fundamental and technical stock information available.
| Year | EPS | Price (INR) | |
|---|---|---|---|
| (MAR) | (INR) | HI | LO |
| 2024 | 21.17 | 1,710 | 1,079 |
| 2023 | 20.40 | 1,216 | 696 |
| 2022 | 15.18 | 886 | 410 |
| 2021 | 11.24 | 0 | 0 |
| 2020 | 15.94 | 0 | 0 |
| 2019 | 13.51 | 0 | 0 |
| 2018 | 8.14 | 0 | 0 |
| 2017 | 0 | 0 | |
| Yield | 0.23% |
| Book Value | 10.37x |
| U/D Vol Ratio | 1 |
| LTDebt/Equity | N.A |
| Alpha | 0.09 |
| Beta | 0.38 |
| EPS Growth Rate | 9% |
| Earnings Stability | 18 |
| P/E Ratio | 57 |
| 5-Year P/E Range | 34-78 |
| Return on Equity | 17% |
| Cash Flow (INR) | 30.19 |
| Date | EPS | %Chg | Sales(Cr) | %Chg | |
|---|---|---|---|---|---|
| Dec-24 | 6.60 | +9% | 381.6 | +19% | |
| Sep-24 | 7.62 | +21% | 403.9 | +27% | |
| Jun-24 | 3.82 | -1% | 315.0 | +17% | |
| Mar-24 | 4.97 | -10% | 325.8 | +8% | |
| Dec-23 | 6.03 | +7% | 321.8 | +11% | |
| Sep-23 | 6.30 | +14% | 318.7 | +7% | |
| Jun-23 | 3.87 | +4% | 270.4 | +21% | |
| Mar-23 | 5.51 | +242% | 302.7 | +51% | |
| Dec-22 | 5.63 | +25% | 290.7 | +23% | |
| Sep-22 | 5.54 | +25% | 297.8 | +18% | |
| Jun-22 | 3.72 | -45% | 222.8 | -6% | |
| Mar-22 | 1.61 | +55% | 201.1 | +32% | |
| Dec-21 | 4.50 | 235.5 | |||
| Sep-21 | 4.42 | 251.8 | |||
| Jun-21 | 6.80 | 236.2 | |||
| Mar-21 | 1.04 | 152.2 | |||
| Dec-20 | |||||
| Sep-20 | |||||
| Jun-20 | |||||
| Mar-20 | 15.94 | 695.1 |
Details tab summarizes key fundamental data essential to analyzing equities. The Details Tab breaks down the data grid so you can better understand the comprehensive fundamental and technical stock information available.
| Year | EPS | Price (INR) | |
|---|---|---|---|
| (MAR) | (INR) | HI | LO |
| 2025e | 27.20 | est | 28.48% |
| 2024 | 21.17 | 1,710 | 1,079 |
| 2023 | 20.40 | 1,216 | 696 |
| 2022 | 15.18 | 886 | 410 |
| 2021 | 11.24 | 0 | 0 |
| 2020 | 15.94 | 0 | 0 |
| 2019 | 13.51 | 0 | 0 |
| 2018 | 8.14 | 0 | 0 |
| 2017 | 0 | 0 | |
| Name | Designation |
|---|---|
| Dr. Ramesh Kancharla | Chairman & Managing Director |
| Dr. Dinesh Kumar Chirla | Whole Time Director |
| Mr. Aluri Srinivasa Rao | Independent Director |
| Dr. Anil Dhawan | Independent Director |
| Ms. Sundari R Pisupati | Independent Director |
| Mr. Santanu Mukherjee | Independent Director |
| Dr. Adarsh Kancharla | Non Executive Director |
| Owner Name | Dec-24 | Sep-24 | Jun-24 | Mar-24 |
|---|---|---|---|---|
| Promoters | 49.85% | 49.85% | 49.88% | 49.83% |
| Mutual Funds | 10.11% | 9.71% | 9.8% | 10.54% |
| Insurance Companies | 1.66% | 1.92% | 1.88% | 1.95% |
| Foreign Portfolio Investors | 25.12% | 25.12% | 24.78% | 24.04% |
| Individual Investors | 10.38% | 10.4% | 10.73% | 10.4% |
| Others | 2.88% | 3% | 2.93% | 3.24% |
| Investor Name | Dec-24 |
|---|---|
| Ramesh Kancharla | 31.04% |
| Chirla Dinesh Kumar Padmarao | 6.53% |
| Adarsh Kancharla | 6.02% |
| Ramesh Kancharla (Kancharla Family Trust) | 5.13% |
| Dsp Equity & Bond Fund | 2.97% |
| Amansa Holdings Private Limited | 2.84% |
| Franklin Templeton Investment Funds | 2.24% |
| Axis Mutual Fund Trustee Ltd A/C Axis Mutual Fund | 1.97% |
| Abu Dhabi Investment Authority - Monsoon | 1.93% |
| Ashoka Whiteoak Icav - Ashoka Whiteoak India Opportunities Fund | 1.52% |
| Hdfc Life Insurance Company Limited | 1.52% |
| Sbi Nifty Smallcap 250 Index Fund | 1.34% |
| Devineni Nagalakshmi | 1.22% |
| Podduturu Preetham Kumar | 1.11% |
| Nippon Life India Trustee Ltd-A/C | 1.07% |
| Chirla Dineshkumar Padma Rao (Sai Geeta Dinesh Trust) | 1.02% |
| Stichting Depositary Apg Emerging Markets Equity Pool Fund | 1.01% |
| Code | Name | Market Cap(Cr) | Master Score | EPS Rank | Price Strength | Buyer Demand | Current Price | Price % Change |
|---|---|---|---|---|---|---|---|---|
| RAINBOW | Rainbow Children's Medicare | 12,947.88 Cr | C | 87 | 65 | C | 1,275.00 | 2.92% |
| APOLLOHOSP | Apollo Hosps.Enterprise | 89,258.85 Cr | B | 91 | 62 | D | 6,207.80 | 1.06% |
| 523323 | Kovai Medical Cntr & Hosp | 5,729.34 Cr | B | 77 | 82 | D+ | 5,236.10 | 1.35% |
| INDRAMEDCO | Indraprastha Med. (Nse) Corp. | 3,130.63 Cr | B | 88 | 80 | D- | 341.50 | 0.06% |
| RAINBOW | Rainbow Children's Medicare | 12,947.88 Cr | C | 87 | 65 | C | 1,275.00 | 2.92% |
Rainbow Children's Medicare has been covered by 2 analysts in the last 6 months. Their average twelve-month price target is Rs. 1,698, suggesting that the stock has a possible upside of 29.28%. The high price target for Rainbow Children's Medicare is Rs. 1,785 and the low price target is Rs. 1,611. There are currently 1 Buy rating, 1 Hold rating.
No obvious concerns with the stock. However, make sure you do the required fundamental & technical analysis before investing
| NSE Additional Surveillance Measure (ASM) list | |
| NSE Graded Surveillance Measure (GSM) list | |
| High Debt Company | |
| No OR limited institutional holding | |
| Penny Stock | |
| High Promoter Pledging | |
| Low liquidity | |
| Decline in number of Institutional Sponsors | |
| Decline in shares held by Institutional Sponsors |
| Client Name | Deal Type | Action | Date | Average Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| BNP PARIBAS ARBITRAGE | BULK | BUY | 2023-09-15 | 1,025.22 | 1,568 | NSE |
| BNP PARIBAS ARBITRAGE | BULK | SELL | 2023-09-15 | 1,023.22 | 6,55,246 | NSE |
| BNP PARIBAS ARBITRAGE | BULK | BUY | 2023-09-15 | 1,025.22 | 1,568 | NSE |
| BNP PARIBAS ARBITRAGE | BULK | SELL | 2023-09-15 | 1,023.22 | 6,55,246 | NSE |
| BNP PARIBAS ARBITRAGE | BULK | BUY | 2023-09-15 | 1,025.22 | 1,568 | NSE |
| BNP PARIBAS ARBITRAGE | BULK | SELL | 2023-09-15 | 1,023.22 | 6,55,246 | NSE |
2017 William O'Neil India Private Limited. All Rights Reserved.
Research Analyst SEBI Regn. Nos: INH000015543 valid till 18 Mar, 2029.
We have recently updated our Privacy Policy. You agree to our updated terms by closing this message box or by continuing to use our site. To read the updated policy, click here
Welcome
We're constantly striving to provide a better experience for our users, to help you invest better, and to keep your data safe and secure. We have updated our Privacy Policy as of May 24, 2018, in accordance with the General Data Protection Regulation (GDPR) law, which will come into effect on May 25, 2018. Please provide consent to continue accessing all of the great content that MarketSmith India has provided you in the past.
Dear valued William O'Neil + Co. user or visitor:
Your privacy is very important to us. As you may be aware, the European Union's General Data Protection Regulation ("GDPR") goes into effect on May 25, 2018. The GDPR is a data privacy regulation that imposes certain data protection obligations on "data controllers" (i.e., companies that decide how your information will be used) and makes the protection of "personal data" (e.g., your name and e-mail address) a fundamental right for residents of the European Union ("EU"). As MarketSmith India processes your personal data as a data controller, we feel it is important to explain how your information will be processed, how it will be shared, how it will be protected, and your rights under the GDPR. Such explanations are provided in our updated Privacy Policy. Please review these documents carefully before you start or continue to use our Services.
Please note that by clicking "Accept and Close" below, you are confirming that you have reviewed the Privacy Policy, understand their contents, are expressly consenting to MarketSmith India's processing activities as detailed therein (including the processing of your data in the United States), and agree to be bound by such agreements. Please note that under the GDPR, you are able to withdraw your consent to MarketSmith India's processing activities at any time. However, even if you withdraw your consent, please note that MarketSmith India will still likely have a legal basis for processing your information, including the bases of contractual necessity and/or legitimate interests. Accordingly, if you do not want MarketSmith India to process your information as detailed in the Privacy Policy, you should refrain from using or accessing the Services.
Earnings Per Share Rating indicates great yearly and recent period earnings growth for Rainbow Children's Medicare.
Great earnings growth is what separates the best stocks from crowd.But it's not enough to just have one or two periods of solid growth. A standout stock needs both a sound growth record in recent years and a strong current earnings record in the last several periods.
As a shortcut for identifying such stocks, MarketSmith developed the Earnings Per Share (EPS) Rating. Indian stocks are ranked on a 1 to 99 scale with 99 being the best. Rainbow Children's Medicare's EPS Rating is 87. The MarketSmith suggests focusing your efforts on stocks with an EPS Rating of at least 80.
Relative Strength Rating indicates mediocre price performance for Rainbow Children's Medicare.
Human nature being what it is, most people invest backwards. They want to buy what is down the most and sell what is up. The best stocks are superior price movers even before their big price moves. You should look for stocks with price leadership.
The MarketSmith Relative Strength (RS) rating shows you which stocks are the best price performers by measuring the stock's performance over the previous 12 months. That performance is then compared with the performance of all other publicly traded companies in India on a 1 to 99 scale, with 99 being the best. Rainbow Children's Medicare's RS Rating is 65. MarketSmith suggests focusing your efforts on stocks with an RS Rating of 80 or more.
Accumulation/Distribution Rating indicates that there is only moderate professional buying of Rainbow Children's Medicare.
Professional investors wield a huge amount of influence over stock's price. Thus it's essential that you buy the better stocks that professionals are buying and that you sell or avoid the ones they may be selling heavily. A quick way to keep track of the end results of professional trading is the Marketsmith Accumulation/Distribution Rating, which is based on daily price and volume changes. It tells you if your stock is under accumulation (professional buying) or distribution (professional selling). Stocks are rated on an A to E scale, with A being the best. Rainbow Children's Medicare's A/D Rating is C. Generally, you should confine your purchases to C or better.
The accumulation and distribution ratings range from +100 to -100. Positive ratings from +100 to 0 means a stock has been showing accumulating. Negative rating from -1 to -10 are neutral, and ratings below -10 mean a stock has been under distribution. The letter ratings range from A+ to E, with stocks with accumulation distribution rating >= +55 rated as A+, >= +45 are rated as A, >= +35 are rated as A-, >= +25 are rated as B+, >= +15 are rated as B, >= +5 are rated as B-, >= 0 are rated as C+, >= -5 are rated as C, >= -10 are rated as C-, >= -15 are rated as D+, >= -20 are rated as D, >= -30 are rated as D- and <= -30 are rated as E.
Industry Group Rank indicates that Rainbow Children's Medicare's industry group Medical-Hospitals has shown strong price performance.
The majority of leading stocks are usually in leading industries. The Marketsmith studies show that roughly half of stock's move is driven by the strength of its respective group.
Marketsmith divides stock into 197 industry groups. We then rank them on six-month price performance, with the #1 group being the best performer. Concentrate your research on stocks in the top 40 groups. Rainbow Children's Medicare is in the Medical-Hospitals Industry Group which ranks 16 of 197
The first step in learning how to pick big stock market winners is to examine leaders of the past to learn the characteristics of the most successful stocks. From these observations, you will be able to recognize the traits these stocks had before their spectacular price advances.
The MarketSmith Master Score combines these characteristics into one easy to use rating. The formula incorporates earnings growth, relative price strength, price-volume characteristics, industry group relative strength and other factors.
In general, concentrate your investment research on stocks with a rating of B or better. Rainbow Children's Medicare's rating is C.
The ratings range from A to E, with stocks with master score >=80 rated as A, 60 to 80 rated as B, 40 to 60 rated as C, 20 to 40 rated as D and 20 to 1 rated as E.
Street Target Price : A price target is an equity analyst's projection of a stock's future price. Analyst determines what the stock's price could be in 12 months which depends on the valuation of the company. These are not our estimates but the maximum, minimum and average derived from Street's estimates based on research coverage on the company. The percentage indicates change from current price.
For example -
OH (OFF High) : Provides an idea about where the stock is currently trading in comparison to its 52-week high price in percentage terms. The formula to calculate OH is current price minus 52-week high price divided by 52-week high price.
OL (OFF Low) : Provides an idea about where the stock is currently trading in comparison to its 52-week low price in percentage terms. The formula to calculate OL is current price minus 52-week low price divided by 52-week low price.
Blue Dot ()
: With RS Line Blue Dot and RS Line Blue Dot List you can catch the strongest
stocks that are outperforming the market. Stocks make the RS Line Blue Dot list when
they satisfy two criteria: 1) When a stock's Relative Strength line hits 52 weeks high
and 2) When it builds a base pattern that signals a potential price jump or When the
stock is breaking out of the Base.
Pattern Recognition ( ) : Pattern Recognition
spotlights any of seven existing or emerging base patterns on MarketSmith Daily and
Weekly stock charts. Learning to identify these base patterns adds an important aspect
of technical stock analysis to your most important investment decisions, particularly
optimum buy and sell points.
Pivot : A pivot represents an area of resistance i.e., a price ceiling at which the stock has previously encountered selling. In our study of winning stocks and their technical breakouts, we have identified pivot as an optimal buy point. When a stock charges above the pivot on above-average trading volume, there is a high probability that it will move even higher.
RS Rating : The Relative Strength Rating looks at a stock's percentage price change over the last 12 months with most recent periods receiving higher weight. All stocks are arranged in order of greatest price percentage change and assigned a rank from 99 (highest) to 1 (lowest). For example, a value of 85 means the stock has outperformed 85% of all other stocks in India.
References :